Evaluation of Electronic Activity Monitors (EAMs) during phase I clinical trials.
Scaranti M, Sundar R, Daly R, Collins D, Dolling D, Gennatas S, Rao Baikady B, Kaye S, Banerji U, Lopez J, De Bono J, Minchom A. Evaluation of Electronic Activity Monitors (EAMs) during phase I clinical trials. Journal Of Clinical Oncology 2019, 37: e18175-e18175. DOI: 10.1200/jco.2019.37.15_suppl.e18175.Peer-Reviewed Original ResearchPhase I trialI trialMean step countPhase I clinical trialPatient's physical functionHeart ratePredicting patient survivalDrug Development UnitStep countsECOG PSPhysical functionPatient survivalElectronic activity monitorsMedical oncologistsRecord heart ratePatient groupPhysician biasTreatment cyclesTreatment decisionsPatientsActivity monitoringPatient outcomesStatistical significanceOSPhysiciansRisk factors for chemotherapy‐induced peripheral neuropathy in patients receiving taxane‐ and platinum‐based chemotherapy
Molassiotis A, Cheng H, Leung K, Li Y, Wong K, Au J, Sundar R, Chan A, De Ng T, Suen L, Chan C, Yorke J, Lopez V. Risk factors for chemotherapy‐induced peripheral neuropathy in patients receiving taxane‐ and platinum‐based chemotherapy. Brain And Behavior 2019, 9: e01312. PMID: 31063261, PMCID: PMC6576180, DOI: 10.1002/brb3.1312.Peer-Reviewed Original ResearchConceptsChemotherapy-induced peripheral neuropathyDevelopment of chemotherapy-induced peripheral neuropathyHistory of neuropathyRisk factorsPeripheral neuropathyPlatinum-based chemotherapySymptom burdenPotential risk factorsVegetable/fruit intakeWHO criteriaChemotherapy cyclesAlcohol intakeSmoking historyUnivariate analysisChemotherapyMultivariate regression modelMedical historyTreatment characteristicsNeurotoxic chemotherapyKey risk factorsNeuropathyCancer CenterSide effectsQuality of lifeTreatment decisions